AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15152059 — intervention group
Group type: COMPARATOR
Intervention: Optimal pharmacologic therapy alone
Number of subjects: 1520
Study 11382723 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rVIIa) 90 microgram/kg
Number of subjects: 0
Study 11382723 — intervention group
Group type: COMPARATOR
Intervention: Nematode anticoagulant protein c2 3.5 microgram/kg
Number of subjects: 0
Study 9289367 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40
Study 9289367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8489989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (BUPI)
Number of subjects: 40
Study 8489989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl subcutaneous infusion (F-SC)
Number of subjects: 40
Study 8489989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus bupivacaine infusion (F-PLX)
Number of subjects: 40
Study 8489989 — intervention group
Group type: COMPARATOR
Intervention: Single block (PLX)
Number of subjects: 40
Study 3114663 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of crystalline melatonin (aMT) administered orally
Number of subjects: 24
Study 3114663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2802036 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic mouthwash
Number of subjects: 12
Study 2802036 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 12
Study 31046809 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 7355
Study 31046809 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 7355
Study 28455091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 770
Study 28455091 — intervention group
Group type: COMPARATOR
Intervention: Attending Physicians
Number of subjects: 770
Study 26029921 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 243
Study 26029921 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 243
Study 26029921 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study 23210544 — intervention group
Group type: EXPERIMENTAL
Intervention: Office bleaching method
Number of subjects: 45
Study 23210544 — intervention group
Group type: EXPERIMENTAL
Intervention: Home bleaching method
Number of subjects: 45
Study 23210544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 45
Study 21810106 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0
Study 21810106 — intervention group
Group type: COMPARATOR
Intervention: 8 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0
Study 21810106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 8 and 16 sessions of psychotherapy combined with pharmacotherapy
Number of subjects: 0
Study 21810106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in remission
Number of subjects: 0
Study 19537522 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg tablet (test preparation)
Number of subjects: 20
Study 19537522 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 10 mg tablet (reference preparation)
Number of subjects: 20
Study 16702182 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ICE (ifosfamide, carboplatin, etoposide combined with rituximab)
Number of subjects: 400
Study 16702182 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP (dexamethasone, ara‐C and cisplatin combined with rituximab)
Number of subjects: 400
Study 16702182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance treatment (375 mg/m2, one injection every 2 months for six times)
Number of subjects: 400
Study 16702182 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group for maintenance treatment)
Number of subjects: 400
Study 15272688 — intervention group
Group type: EXPERIMENTAL
Intervention: QWIP (quantum well infrared photodetector) imaging technique
Number of subjects: 6
Study 15272688 — intervention group
Group type: COMPARATOR
Intervention: NIRS and LDF measurements
Number of subjects: 6
Study 11511335 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19
Study 11511335 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study 11511335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 19
Study 9024711 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 386
Study 9024711 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 386
Study 9024711 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 386
Study 9024711 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 386
Study 8342318 — intervention group
Group type: EXPERIMENTAL
Intervention: 1991‐1992 trivalent split influenza vaccine (A/Singapore/6/86 (H1N1), A/Beijing/353/89 (H3N2), B/Yamagata/16/88)
Number of subjects: 296
Study 8342318 — intervention group
Group type: COMPARATOR
Intervention: H3N2 and B components
Number of subjects: 296
Study 3569766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg)
Number of subjects: 20
Study 3569766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, q.i.d. for 4 weeks)
Number of subjects: 20
Study 3569766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 3569766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31752637 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 1624
Study 31752637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1624
Study 27986357 — intervention group
Group type: EXPERIMENTAL
Intervention: Less dilated left ventricles (EDVI < 90 mL/m2)
Number of subjects: 260
Study 27986357 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in baseline dyssynchrony
Number of subjects: 260
Study 27986357 — intervention group
Group type: COMPARATOR
Intervention: Severely dilated left ventricles (EDVI ≥ 90 mL/m2)
Number of subjects: 260
Study 25102205 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine/low volume group (2 μg/kg per hour norepinephrine + 1 ml/kg per hour initially and 3 ml/kg per hour crystalloid infusion after cystectomy)
Number of subjects: 93
Study 25102205 — intervention group
Group type: COMPARATOR
Intervention: Standard crystalloid infusion group (6 ml/kg per hour throughout surgery)
Number of subjects: 93
Study 25102205 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine/low volume group
Number of subjects: 93
Study 25102205 — intervention group
Group type: COMPARATOR
Intervention: Standard crystalloid infusion group
Number of subjects: 93
Study 23798626 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 65
Study 23798626 — intervention group
Group type: COMPARATOR
Intervention: Expressed Breast Milk (EBM)
Number of subjects: 65
Study 21415720 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 1 Hz 80% resting motor threshold (rMT)
Number of subjects: 65
Study 21415720 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 1 Hz 100% rMT
Number of subjects: 65
Study 21415720 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 10 Hz 80% rMT
Number of subjects: 65
Study 21415720 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 10 Hz 100% rMT
Number of subjects: 65
Study 21415720 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS stimulation at 50 Hz triplets at 90% of active motor threshold (intermittent theta-burst)
Number of subjects: 65
Study 21415720 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 65
Study 18971883 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (12 g at the beginning of the operation)
Number of subjects: 120
Study 18971883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16782917 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, paclitaxel, and carboplatin (TPC)
Number of subjects: 196
Study 16782917 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and paclitaxel (TP)
Number of subjects: 196
Study 16782917 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, paclitaxel, and carboplatin (TPC) in HER‐2 3+ patients
Number of subjects: 196
Study 16782917 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and paclitaxel (TP) in HER‐2 3+ patients
Number of subjects: 196
Study 12707726 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG-IDA (fludarabine 30 mg/m(2), AraC 2 g/m(2) for 5 days, idarubicin 10 mg/m(2) for 3 days, G‐CSF 5 micro g/kg from day +6 until neutrophil recovery)
Number of subjects: 46
Study 12707726 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG-IDA
Number of subjects: 46
Study 10522638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballet dancers
Number of subjects: 126
Study 10522638 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 126
Study 7494233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via two-vessel treatment
Number of subjects: 102
Study 7494233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via one-vessel treatment
Number of subjects: 102
Study 7494233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy via middle-cerebral artery treatment
Number of subjects: 102
Study 7494233 — intervention group
Group type: COMPARATOR
Intervention: Control group in the BTCG phase III trial of intra-arterial chemotherapy
Number of subjects: 102
Study 1788749 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusion of 40 micrograms PGE1 in 125 ml saline over 60 min
Number of subjects: 20
Study 1788749 — intervention group
Group type: COMPARATOR
Intervention: i.a. infusion of 10 micrograms PGE1 in 25 ml saline over 30 min
Number of subjects: 20
Study 6756705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 6
Study 6756705 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion (5, 10, and 20 ng/kg/min)
Number of subjects: 6
Study 6756705 — intervention group
Group type: COMPARATOR
Intervention: Control infusions (placebo)
Number of subjects: 6
Study 31738113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 386
Study 31738113 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 386
Study 29482649 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy (5-fluorouracil 300 mg/m2 continuous infusion for 96 h plus paclitaxel 50 mg/m2 on day 1 for 5 weeks) followed by consolidation chemotherapy (5-fluorouracil 1800 mg/m2 continuous infusion for 72 h plus paclitaxel 175 mg/m2 on day 1 for 2 cycles)
Number of subjects: 436
Study 29482649 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus 5-fluorouracil (PF) concurrent with radiotherapy (cisplatin 25 mg/m2/d on days 1-3 plus 5-fluorouracil 1800 mg/m2 continuous infusion for 72 h for 2 cycles) followed by consolidation chemotherapy for 2 cycles
Number of subjects: 436
Study 26992007 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional phase with soft tissue conditioning using the 'dynamic compression technique' (Group 1)
Number of subjects: 20
Study 26992007 — intervention group
Group type: COMPARATOR
Intervention: Without a provisional (Group 2)
Number of subjects: 20
Study 26992007 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional phase with soft tissue conditioning (Group 1)
Number of subjects: 20
Study 23901798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 133
Study 23901798 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 133
Study 22374842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flour inhalation challenge
Number of subjects: 10
Study 22374842 — intervention group
Group type: COMPARATOR
Intervention: Control inhalation challenge
Number of subjects: 10
Study 21186929 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment combined with contingency management for up to 12 weeks
Number of subjects: 152
Study 21186929 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of delay discounting
Number of subjects: 152
Study 21186929 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and income
Number of subjects: 152
Study 18609150 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkilned oats
Number of subjects: 32
Study 18609150 — intervention group
Group type: COMPARATOR
Intervention: Kilned oats
Number of subjects: 32
Study 15703367 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21)
Number of subjects: 24
Study 15703367 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study 11978685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 61
Study 11978685 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI 30)
Number of subjects: 61
Study 11978685 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin lispro 25 (Mix25)
Number of subjects: 61
Study 11978685 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 61
Study 11907926 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for menopause (specific treatments not detailed)
Number of subjects: 0
Study 11907926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration systematic reviews
Number of subjects: 0
Study 7665807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine continuation therapy
Number of subjects: 41
Study 2468920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 0
Study 2468920 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg b.i.d.)
Number of subjects: 0
Study 2468920 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg b.i.d.)
Number of subjects: 0
Study 2468920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (digoxin alone)
Number of subjects: 0
Study 792358 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 113
Study 792358 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (150 or 200 mg every hr)
Number of subjects: 113
Study 792358 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (60-80 mg every 8 hr)
Number of subjects: 113
Study 31543954 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwritten invitation letter
Number of subjects: 317
Study 31543954 — intervention group
Group type: COMPARATOR
Intervention: Printed invitation letter
Number of subjects: 317
Study 31543954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 317
Study 31543954 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 317
Study 28471840 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 2558
Study 28471840 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care CD4 Count Testing (POC CD4)
Number of subjects: 2558
Study 28471840 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Facilitation (CF)
Number of subjects: 2558
Study 28471840 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport Reimbursement
Number of subjects: 2558
Study 25829124 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltimore Healthy Eating Zones intervention
Number of subjects: 242
Study 24201232 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus amantadine (100 mg/d for patients <30 kg or 150 mg/d for patients >30 kg)
Number of subjects: 40
Study 24201232 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus amantadine
Number of subjects: 40
Study 24201232 — intervention group
Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study 21529927 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler closure
Number of subjects: 450
Study 21529927 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn closure
Number of subjects: 450
Study 19892078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Seeking Safety; SS) plus treatment-as-usual (TAU)
Number of subjects: 49
Study 19892078 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 49
Study 19892078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Seeking Safety; SS)
Number of subjects: 49
Study 19892078 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (SS and TAU)
Number of subjects: 49
Study 16924035 — intervention group
Group type: COMPARATOR
Intervention: Single PYGM mutation carriers
Number of subjects: 26
Study 16924035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with McArdle disease
Number of subjects: 26
Study 16924035 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 26
Study 15253846 — intervention group
Group type: EXPERIMENTAL
Intervention: lavender oil
Number of subjects: 7
Study 15253846 — intervention group
Group type: EXPERIMENTAL
Intervention: thyme oil
Number of subjects: 7
Study 15253846 — intervention group
Group type: COMPARATOR
Intervention: unscented grapeseed oil
Number of subjects: 7
Study 11475459 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Contact Cast (TCC)
Number of subjects: 9
Study 11475459 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Pneumatic Pre‐fabricated Walking Brace (PWB)
Number of subjects: 9
Study 11475459 — intervention group
Group type: COMPARATOR
Intervention: Running Shoe (RS)
Number of subjects: 9
Study 9236587 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 14 days
Number of subjects: 360
Study 9236587 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate for 28 days
Number of subjects: 360
Study 9236587 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V for 14 days
Number of subjects: 360
Study 9236587 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V for 28 days
Number of subjects: 360
Study 8537919 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-curing composite resin cement
Number of subjects: 25
Study 8537919 — intervention group
Group type: COMPARATOR
Intervention: Dual-curing composite resin cement
Number of subjects: 25
Study 8537919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlays inserted in molars
Number of subjects: 25
Study 8537919 — intervention group
Group type: COMPARATOR
Intervention: Inlays inserted in premolars
Number of subjects: 25
Study 2677260 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU), 600 mg/m2/week for 6 weeks (arm A)
Number of subjects: 80
Study 2677260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + folinic acid (FA), 200 mg/m2/week for 6 weeks (arm B)
Number of subjects: 80
Study 2677260 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU, 600 mg/m2/week for 6 weeks (arm A)
Number of subjects: 80
Study 2677260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + FA, 200 mg/m2/week for 6 weeks (arm B)
Number of subjects: 80
Study 2677260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + FA (arm B)
Number of subjects: 80
Study 2677260 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU (arm A)
Number of subjects: 80
Study 367679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 fractions in 22 days
Number of subjects: 98
Study 367679 — intervention group
Group type: COMPARATOR
Intervention: 30 fractions in 42 days
Number of subjects: 98
Study 31830535 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game-based occupational therapy (VG)
Number of subjects: 51
Study 31830535 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 51
Study 31419257 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls Active programme
Number of subjects: 997
Study 31419257 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997
Study 27841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (BG: 100‐140 mg/dL)
Number of subjects: 302
Study 27841946 — intervention group
Group type: COMPARATOR
Intervention: Conservative glycemic control (BG: 141‐180 mg/dL)
Number of subjects: 302
Study 27841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 302
Study 27841946 — intervention group
Group type: COMPARATOR
Intervention: Conservative glycemic control
Number of subjects: 302
Study 27841946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and Conservative glycemic control
Number of subjects: 302
Study 24197754 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic whole body vibration (WBV) applied for four days, five stimulus trains of 60 seconds at a frequency of 6.5 Hz with 60 seconds resting time between stimuli (n=17).
Number of subjects: 32
Study 24197754 — intervention group
Group type: COMPARATOR
Intervention: Sham group received the same treatment with 1 Hz (n=15).
Number of subjects: 32
Study 22454004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible (MIB) regimen
Number of subjects: 1067
Study 22454004 — intervention group
Group type: COMPARATOR
Intervention: Conventional 28-day regimen
Number of subjects: 1067
Study 22454004 — intervention group
Group type: COMPARATOR
Intervention: Fixed extended regimen
Number of subjects: 1067
Study 20012450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performing group (HP)
Number of subjects: 24
Study 20012450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-performing group (LP)
Number of subjects: 24
Study 20012450 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak treadmill running velocity (PV), running economy (RE), lactate threshold (LT)
Number of subjects: 24
Study 18723699 — intervention group
Group type: EXPERIMENTAL
Intervention: Alder Hey Triage Pain Score (AHTPS)
Number of subjects: 75
Study 18723699 — intervention group
Group type: COMPARATOR
Intervention: Wong-Baker Faces Pain Rating Scale (WBS)
Number of subjects: 75
Study 18723699 — intervention group
Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 75